drugset / Trial / NCT00005786

Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia

NCT00005786

Terminated 25 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have relapsed or refractory lymphoma or leukemia. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

Timeline

Start
2001-01
Primary completion
2004-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject arsenic trioxide Small molecule Intravenous